What insurance policy changes affect code E80.0?

There are 3 tracked policy changes affecting code E80.0, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E80.0?

Payers that have issued tracked updates for code E80.0 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code E80.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E80.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E80.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

E80.0 Insurance Policy Changes

ICD-10 E80.0 is officially defined as "Hereditary erythropoietic porphyria." code E80.0 is referenced in 3 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E80.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Genetic Diseases (CPB 0871, reviewed 2025-12-22)
Aetna considers allogeneic hematopoietic cell transplantation medically necessary for alpha-mannosidosis, childhood-onset adrenoleukodystrophy, Fanconi anemia under stated criteria, erythropoietic protoporphyria with severe hepatopathy, fucosidosis, globoid cell leukodystrophy (Krabbe disease), metachromatic leukodystrophy, mucolipidoses, mucopolysaccharidoses, and Wolman disease. It also considers allogeneic transplant medically necessary for children with infantile malignant osteopetrosis confirmed by bone biopsy and radiographic imaging who do not have irreversible neurologic impairment or multi-organ failure. Allogeneic transplant for Barakat syndrome, autologous transplant for infantile malignant osteopetrosis, mucopolysaccharidosis or childhood-onset adrenoleukodystrophy, and hematopoietic cell transplantation (autologous, allogeneic or cord blood) for hereditary corneal defects, Huntington's disease or TRNT1 enzyme deficiency are considered experimental, investigational or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Afamelanotide (Scenesse) (CPB 0962, reviewed 2025-12-09)
Aetna considers afamelanotide (Scenesse) medically necessary for biochemically confirmed erythropoietic protoporphyria in adult members whose protoporphyrin level is above the lab reference range in peripheral red blood cells. Aetna considers continuation of afamelanotide therapy medically necessary for adult members with that indication who are experiencing benefit from therapy while receiving it. Aetna considers all other indications experimental, investigational, or unproven, including inhibition of drug-resistant pathogenic bacteria such as MRSA and treatment of acute ischemic stroke, and this policy applies to commercial medical plans.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Low impact
Phlebotomy, Therapeutic
This is a policy review for therapeutic phlebotomy coverage under BCBS Mississippi. The policy confirms coverage for specific blood disorders including polycythemia vera, hemochromatosis, and related conditions. No changes were made to coverage criteria or billing codes.

Watch E80.0

Get one email when a payer policy names E80.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Genetic Diseases (CPB 0871, reviewed 2025-12-22)

Afamelanotide (Scenesse) (CPB 0962, reviewed 2025-12-09)

Phlebotomy, Therapeutic

What insurance policy changes affect code E80.0?

Which payers have updated policy for code E80.0?

How do I get notified when code E80.0 policy changes?

Why do payers change policies for code E80.0?